In a randomised, double blind, long term, crossover study 1 g twice daily of methenamine hippurate was compared with placebo for its preventive effect on recurrent attacks of acute cystitis. Methenamine hippurate and placebo were interchanged every six months for two years. During one of the years patients took 250 ml extra fluid every morning and evening. Out of 21 enrolled patients, 14 completed the first year and 13 both years of treatment, which permitted the evaluation of 27 patient years. There were 52 episodes ofacute cystitis caused by reinfection: 41 occurred during placebo treatment and only 11 during the methenamine hippurate regimen (p<0-01). Extra fluid intake did not reduce the incidence of acute cystitis, nor did it reduce the effect of methenamine hippurate.
Introduction
Methenamine was introduced for treating urinary tract infections a century ago.' Despite reports of a preventive effect on recurrent acute cystitis23 its efficacy has remained questionable. 4 Discussion We found 2-1 infections per patient/year with placebo but only 0-8 with methenamine hippurate (p<00 1). These figures are better than those reported after administration of 2 g methenamine mandelate together with 2 g ascorbic acid, indicating that ascorbic acid is unnecessary.
Because methenamine hippurate is well tolerated, is effective, and fails to produce cross resistance to conventional antibiotics it seems to be a suitable prophylactic agent against recurrent acute cystitis in women.
